Your browser doesn't support javascript.
loading
Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines.
Luo, Xi; Maciaszek, Jamie L; Thompson, Bryony A; Leong, Huei San; Dixon, Katherine; Sousa, Sónia; Anderson, Michael; Roberts, Maegan E; Lee, Kristy; Spurdle, Amanda B; Mensenkamp, Arjen R; Brannan, Terra; Pardo, Carolina; Zhang, Liying; Pesaran, Tina; Wei, Sainan; Fasaye, Grace-Ann; Kesserwan, Chimene; Shirts, Brian H; Davis, Jeremy L; Oliveira, Carla; Plon, Sharon E; Schrader, Kasmintan A; Karam, Rachid.
Afiliación
  • Luo X; Department of Pediatrics/Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
  • Maciaszek JL; Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Thompson BA; Department of Pathology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Leong HS; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Dixon K; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Sousa S; Instituto de Investigação e Inovação em Saúde - (i3S), University of Porto, Porto, Portugal.
  • Anderson M; Institute of Molecular Pathology and Immunology - (IPATIMUP), University of Porto, Porto, Portugal.
  • Roberts ME; Invitae Corporation, San Francisco, California, USA.
  • Lee K; The Ohio State University, Columbus, Ohio, USA.
  • Spurdle AB; Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Mensenkamp AR; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Brannan T; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Pardo C; Ambry Genetics, Aliso Viejo, California, USA.
  • Zhang L; Invitae Corporation, San Francisco, California, USA.
  • Pesaran T; Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Wei S; Ambry Genetics, Aliso Viejo, California, USA.
  • Fasaye GA; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky, USA.
  • Kesserwan C; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Shirts BH; National Institutes of Health, Bethesda, Maryland, USA.
  • Davis JL; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Oliveira C; Surgical Oncology Program, National Cancer Institute, Bethesda, Maryland, USA.
  • Plon SE; Instituto de Investigação e Inovação em Saúde - (i3S), University of Porto, Porto, Portugal.
  • Schrader KA; Institute of Molecular Pathology and Immunology - (IPATIMUP), University of Porto, Porto, Portugal.
  • Karam R; Department of Pathology, University of Porto, Porto, Portugal.
J Med Genet ; 60(6): 568-575, 2023 06.
Article en En | MEDLINE | ID: mdl-36600593
ABSTRACT

BACKGROUND:

Germline pathogenic variants in CDH1 are associated with increased risk of diffuse gastric cancer and lobular breast cancer. Risk reduction strategies include consideration of prophylactic surgery, thereby making accurate interpretation of germline CDH1 variants critical for physicians deciding on these procedures. The Clinical Genome Resource (ClinGen) CDH1 Variant Curation Expert Panel (VCEP) developed specifications for CDH1 variant curation with a goal to resolve variants of uncertain significance (VUS) and with ClinVar conflicting interpretations and continues to update these specifications.

METHODS:

CDH1 variant classification specifications were modified based on updated genetic testing clinical criteria, new recommendations from ClinGen and expert knowledge from ongoing CDH1 variant curations. The CDH1 VCEP reviewed 273 variants using updated CDH1 specifications and incorporated published and unpublished data provided by diagnostic laboratories.

RESULTS:

Updated CDH1-specific interpretation guidelines include 11 major modifications since the initial specifications from 2018. Using the refined guidelines, 97% (36 of 37) of variants with ClinVar conflicting interpretations were resolved to benign, likely benign, likely pathogenic or pathogenic, and 35% (15 of 43) of VUS were resolved to benign or likely benign. Overall, 88% (239 of 273) of curated variants had non-VUS classifications. To date, variants classified as pathogenic are either nonsense, frameshift, splicing, or affecting the translation initiation codon, and the only missense variants classified as pathogenic or likely pathogenic have been shown to affect splicing.

CONCLUSIONS:

The development and evolution of CDH1-specific criteria by the expert panel resulted in decreased uncertain and conflicting interpretations of variants in this clinically actionable gene, which can ultimately lead to more effective clinical management recommendations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Variación Genética Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: J Med Genet Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Variación Genética Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: J Med Genet Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos